The WACC of Chunghwa Chemical Synthesis & Biotech Co Ltd (1762.TW) is 9.6%.
| Range | Selected | |
| Cost of equity | 5.40% - 8.20% | 6.80% |
| Tax rate | 18.90% - 19.70% | 19.30% |
| Cost of debt | 13.80% - 28.00% | 20.90% |
| WACC | 7.0% - 12.2% | 9.6% |
| Category | Low | High |
| Long-term bond rate | 2.0% | 2.5% |
| Equity market risk premium | 6.0% | 7.0% |
| Adjusted beta | 0.56 | 0.74 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 5.40% | 8.20% |
| Tax rate | 18.90% | 19.70% |
| Debt/Equity ratio | 0.38 | 0.38 |
| Cost of debt | 13.80% | 28.00% |
| After-tax WACC | 7.0% | 12.2% |
| Selected WACC | 9.6% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for 1762.TW:
cost_of_equity (6.80%) = risk_free_rate (2.25%) + equity_risk_premium (6.50%) * adjusted_beta (0.56) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.